|
Report No. : |
357258 |
|
Report Date : |
28.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
BARRETT HODGSON PAKISTAN (PRIVATE) LTD |
|
|
|
|
Registered Office : |
F-423, S.I.T.E.,
Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
1992 |
|
|
|
|
Com. Reg. No.: |
0028289 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & marketing of different pharmaceutical
class like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine,
Narcotic Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones,
Vitamins, Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide, Calcium-Antagonist,
Cardio Selective Beta Blocker |
|
|
|
|
No. of Employee : |
332 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 65,092 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
PAKISTAN - ECONOMIC OVERVIEW
Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fourth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to diversify its exports has left the country vulnerable to shifts in world demand. Official unemployment was 6.9% in 2014, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Pakistan's human development continues to lag behind most of the region.. As a result of political and macroeconomic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 to preventa balance of payments crisis, but the IMF ended the Arrangement early because of Pakistan's failure to implement required reforms. The economy has stabilized, it continues to underperform and foreign investment has not returned to levels seen during the mid-2000s, due to investor concerns related to governance, electricity shortages, , and a slow-down in the global economy. Remittances from overseas workers, averaging more than$1 billion a month, remain a bright spot for Pakistan. After a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to a deficit where it remained through 2014, spurred by higher prices for imported oil and lower prices for exported cotton. In September 2013, after facing balance of payments concerns, Pakistan entered into a three-year, $6.7 billion IMF Extended Fund Facility. The Sharif government has since made modest progress implementing fiscal and energy reforms, and in December 2014 the IMF described Pakistan's progress as "broadly on track." Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3.5% per year from 2008 to 2014. Pakistan must address long standing issues related to government revenues and the electricity and natural gas sectors in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.
|
Source
: CIA |
BARRETT HODGSON
PAKISTAN (PRIVATE) LTD
|
Registered
Address & Factory |
|
F-423, S.I.T.E.,
Karachi, Pakistan |
|
Tel # |
92 (21) 32570651
- 57 (7 Lines) |
|
Fax # |
92 (21) 32568827,
32570650 |
|
a. |
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1992 |
|
c. |
Registration No. |
0028289 |
|
Address |
1-A, Shahid Plaza, Jinnah Avenue, Blue Area, Islamabad, Pakistan |
|
Tel # |
92 (51) 2277098, 2270275 |
|
Fax # |
92 (51) 2270277 |
|
Address |
175, Gen. Sarfraz Khan Road, Shadman-II, Lahore, Pakistan |
|
Tel # |
92 (42) 37562711, 37562705 |
|
Fax # |
92 (42) 37582854 |
|
A.F. Ferguson & Co. (Chartered
Accountants) State Life Building, 1-C, Off: I.I. Chundrigar Road, Karachi, Pakistan |
|
Subject Company was established as a Private Limited Company in 1992 |
|
6. |
Authorized Capital |
Rs. 250,000,000/-
divided into 2,500,000 shares of Rs. 100/- each |
|
|
Issued & Paid up Capital |
Rs. 136,570,000/-
divided into 1,365,700 shares of Rs. 100/- each |
|
Names |
Designation |
|
Dr. S.M Habib Mr. Muhammad
Feroz Alam Mr. Muhammad
Abbas Dr. M.S Habib Dr. Iram Afaq Dr. Hasan Tharani |
Chief Executive Director Director Director Director Director |
|
Names |
No. of Shares |
|
Barrett Hodgson
Limited, U.K. Dr. M.S. Habib Dr. Iram Afaq The Salim Habib
Education Foundation, Pakistan |
1,207,279 57,599 1 100,821 |
A. Subsidiary
None
B. Associated
Companies
Lahore Medical Instruments (Pvt) Limited, Pakistan.
Manufacture & marketing of different pharmaceutical class
like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic
Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins,
Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide,
Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of ACICON, BAMBEC, BAYHEP, BETALOC ZOK,
BETAXEN, BINADEX, BRICANYL, CEFAMEZIN, CEFCOM, CEFIX, CEFIZOX, CEFNIR, CEFSPAN,
CIPOCAINE, CIPOTIC, DOMEL, DYNAQUIN, ERADEP, EXOCIN, FEBROL, FLUCOL, GENTICYN,
GIXER, INOCEF, INOQUIN, JECTOFER, LEVAQUIN, MOBIKARE GEL, MST CONTINUS,
MYLAXON, OCUFEN, PENGLOBE, PERSCH, PLENDIL, POLYFER, PRED FORTE, PULMICORT,
QUINTEC, RECOL, ROMICEF, SARTAN, WINTAX, XYLOAID, XYLOCAINE, ADRENALINE
332
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves varying processes of
manufacture
|
Years |
In
Pak Rupees |
|
2013 2014 |
3,579,569,000/- 4,481,869,000/- |
ASTRAZENECA, U.K.
ASTELLAS DEUTSCHLAND GMBH, GERMANY.
MIKA PHARMA GMBH, GERMANY.
ALLERGAN, U.S.A.
ZHEJIANG JINGXIN PHARMACEUTICAL IMPORT & EXPORT, CHINA.
|
More than 100 Distributors in all over Pakistan |
|
Mainly to Asian, Middle East and European Countries |
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 106.20 |
|
UK Pound |
1 |
Rs. 158.20 |
|
Euro |
1 |
Rs. 115.00 |
Subject Company was established in 1992 and is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation is extremely good. Directors are reported as resourceful and experienced professionals. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.20 |
|
UK Pound |
1 |
Rs.98.30 |
|
Euro |
1 |
Rs.72.41 |
|
PKR |
1 |
Rs. 0.63 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.